Northwest Biotherapeutics | NWBO - Equity Capital And Reserves


Northwest Biotherapeutics reported $-108.65M in Equity Capital and Reserves for its fiscal quarter ending in September of 2025.





Equity Capital And Reserves Change Date
Agenus USD -274.14M 80.46M Sep/2025
AstraZeneca USD 48.67B 2.78B Dec/2025
Bristol-Myers Squibb USD 18.55B 1.06B Sep/2025
Celldex Therapeutics USD 598.36M 57.04M Sep/2025
Eisai JPY 889.64B 35.21B Dec/2025
Infinity Pharmaceuticals USD -37.41M 9.08M Jun/2023
Merck USD 51.85B 2.79B Sep/2025
Northwest Biotherapeutics USD -108.65M 8.26M Sep/2025
Pfizer USD 92.8B 4.11B Sep/2025
Plus Therapeutics USD -1.35M 3.97M Dec/2023
Roche Holding CHF 33.8B 758M Dec/2025